Page last updated: 2024-12-07
wy 50324
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
WY 50324: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 130918 |
| CHEMBL ID | 545793 |
| CHEMBL ID | 1194252 |
| CHEMBL ID | 2111138 |
| SCHEMBL ID | 247559 |
| MeSH ID | M0216811 |
Synonyms (30)
| Synonym |
|---|
| w5u6wqm26h , |
| tricyclo(3.3.1.1(3,7))decane-1-carboxamide, n-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)- |
| unii-w5u6wqm26h |
| 127266-56-2 |
| adatanserin [inn] |
| wy 50324 |
| wy-50324 |
| adatanserin |
| adamantane-1-carboxylic acid [2-(4-pyrimidin-2-yl-piperazin-1-yl)-ethyl]-amide; dihydrochloride |
| bdbm50083287 |
| CHEMBL545793 , |
| L001372 |
| n-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide |
| CHEMBL1194252 |
| n-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)tricyclo(3.3.1.1(sup (3.7))decane-1-carboxamide |
| n-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)-1-adamantanecarboxamide |
| tricyclo(3.3.1.13,7)decane-1-carboxamide, n-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl) |
| SCHEMBL247559 |
| smr004703314 |
| MLS006011548 |
| CHEMBL2111138 |
| Z749259376 |
| sr-01000945138 |
| SR-01000945138-1 |
| n-{2-[4-(pyrimidin-2-yl)piperazin-1-yl]ethyl}adamantane-1-carboxamide |
| Q4680877 |
| DTXSID90869749 |
| tricyclo[3.3.1.13,7]decane-1-carboxamide, n-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- |
| EN300-1700020 |
| AKOS040745482 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||